Full-Time

Associate Director

Learning & Development, Marketing Excellence, Global Capability Op Model & Data

Updated on 9/3/2026

Jazz Pharmaceuticals

Jazz Pharmaceuticals

1,001-5,000 employees

Biopharmaceuticals focused on neuroscience and oncology

Compensation Overview

$156k - $234k/yr

+ Discretionary Annual Cash Bonus + Discretionary Equity Grants

Pennsylvania, USA

Remote

US-based, home-based in Pennsylvania; travel up to 50-60% locally/visits as needed.

Bachelor's, MBA

Category
People & HR (1)
Required Skills
Branding/Brand Strategy
Data Governance
Data Analysis

Get referred to Jazz Pharmaceuticals

See people who can refer or advise you

Requirements
  • Bachelor's degree in business, healthcare, technology, or related field
  • 10 years of industry experience in marketing, preferably in specialty pharmaceuticals/biotech, data and/or IT related roles
  • 2+ years of experience in training, with a proven track record of developing and delivering engaging training solutions using adult learning principles and distance learning methodologies
Responsibilities
  • Own and execute the enterprise learning and adoption strategy for Marketing Excellence capabilities, establishing global curricula, capability development pathways, and role-based learning experiences that progress from foundational to advanced levels and align with commercial priorities, capability roadmaps, and transformation initiatives.
  • Serve as the strategic advisor to Commercial Leadership, Global Capability leaders, and franchise leadership on marketing capability development priorities and organizational readiness.
  • Design and scale role-based onboarding and capability development programs that strengthen core marketing excellence skills—including brand strategy, insight-driven planning, executional excellence, analytics, and decision-making—by translating frameworks, playbooks, and best practices into practical learning experiences.
  • Lead enterprise adoption of Marketing Excellence standards, new ways of working, and customer engagement models through integrated learning, performance consulting, change management, and capability-building interventions that drive sustained behavior change, operational excellence, and business readiness.
  • Partner with Global Capability, Commercial, Analytics, Brand, and Data & Enablement leaders to develop learning solutions that build understanding and adoption of the Global Capability Operating Model, including roles, responsibilities, decision rights, and enterprise ways of working.
  • Develop and oversee learning programs that enable marketers to understand, access, interpret, and appropriately apply commercial data assets, including data governance principles, ownership models, access requirements, limitations, and intended business use.
  • Present capability insights, adoption metrics, risks, recommendations, and organizational readiness assessments to executive leadership teams.
  • Facilitate leadership alignment around capability evolution, organizational readiness, and performance improvement opportunities.
  • Establish measurement frameworks to assess learning effectiveness, capability adoption, behavior change, and organizational impact; leverage stakeholder feedback, performance metrics, and emerging industry trends to continuously evolve learning priorities and programs.
  • Build organizational capability within the Learning & Development function through mentoring, knowledge sharing, and best-practice development.
  • Collaborate cross‑functionally with Franchises, Customer Insights & Analytics, Legal, and Compliance to ensure marketing excellence content is accurate, practical, and compliant
  • Collaborate cross‑functionally with Global Capability Teams, DEC, and Compliance partners to ensure accuracy, alignment, and appropriate use guidance.
  • Collaborate with adjacent L&D team members to ensure alignment across curricula.
  • Engage regional stakeholders to drive consistent adoption while accounting for local needs.
  • Share insights, risks, and lessons learned with CX peers and team leadership to support alignment and continuous improvement
Desired Qualifications
  • Advanced degree (MBA or relevant graduate degree) preferred.
  • Leadership experience in marketing preferred, including strategy development and cross-functional collaboration to drive marketing effectiveness and capability building.
  • Experience working in a product operating model.
  • Experience in healthcare, pharmaceutical, or other highly regulated industries preferred.

Jazz Pharmaceuticals develops and markets therapies in neuroscience and oncology. Its products include Xyrem and the lower-sodium option Xywav for narcolepsy, Epidiolex for seizures in severe epilepsy, and oncology medicines Zepzelca for small cell lung cancer and Vyxeos for AML, with Epidiolex being cannabidiol-based. The company grows its portfolio through a mix of in-house R&D and strategic acquisitions that broaden its specialty-drug lineup and global reach. Its goal is to expand approved treatments and the pipeline to help patients with limited options by building a diversified, specialty-focused portfolio.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dublin, Ireland

Founded

2003

Get referred to Jazz Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Second-quarter 2026 revenue reached $1.21 billion, and full-year guidance rose to $4.60-$4.75 billion.
  • Ziihera approval on August 25, 2026 opens a $3 billion-$5 billion peak-sales opportunity.
  • Zepzelca and Xywav posted strong 2026 growth, validating Jazz's oncology and sleep franchises.

What critics are saying

  • Lupin, Teva, and Tris challenge Xywav and Xyrem, threatening 2027-2033 economics.
  • Granules settled in March 2026 with launch rights under confidential terms, pressuring Xywav pricing.
  • Jazz took on Actio for $820 million upfront; ABS-1230 still faces clinical and regulatory failure.

What makes Jazz Pharmaceuticals unique

  • Xywav owns narcolepsy and idiopathic hypersomnia through FDA orphan exclusivity until July 2027.
  • Epidiolex gives Jazz rare epilepsy scale, with durable U.S. brand recognition since 2021 GW acquisition.
  • Ziihera launch on August 25, 2026 expands Jazz into HER2-positive gastroesophageal cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

0%
StockTitan
Aug 27th, 2026
Jazz Pharmaceuticals prices upsized $1.1B exchangeable notes offering with $225M share repurchase

Jazz Pharmaceuticals has priced an upsized $1.1 billion private offering of 1.875% exchangeable senior notes due 2032, up from the previously announced $1.0 billion. The offering, conducted through its wholly-owned subsidiary Jazz Investments I Limited, is expected to close on 31 August 2026. The notes will mature on 15 September 2032 and are exchangeable at an initial rate of 2.8150 ordinary shares per $1,000 principal amount, equivalent to an exchange price of approximately $355.24 per share. This represents a 42.5% premium above the last reported sale price on 26 August 2026. The company will use net proceeds of approximately $1,079 million for general corporate purposes. Concurrently, Jazz Pharmaceuticals agreed to repurchase approximately $225 million of its ordinary shares from note purchasers at $249.29 per share, using existing cash on hand.

Yahoo Finance
Aug 26th, 2026
Jazz Pharmaceuticals launches Ziihera for HER2-positive cancer with $3B–$5B peak sales outlook

Jazz Pharmaceuticals has launched Ziihera in the US following FDA approval for first-line treatment of HER2-positive, unresectable or metastatic gastroesophageal adenocarcinoma. The drug can be used with tislelizumab and chemotherapy, or with chemotherapy alone for certain patients. In the Phase III HERIZON-GEA-01 trial, Ziihera-based regimens reduced the risk of disease progression or death by 35%. The triplet regimen extended median overall survival to 26.4 months, a 28% reduction in death risk versus trastuzumab. Jazz estimates the US addressable market at 3,000–4,000 patients annually and raised Ziihera's peak sales outlook to $3 billion–$5 billion. The company plans to leverage existing commercial infrastructure whilst pursuing additional cancer indications and international regulatory filings.

Yahoo Finance
Aug 11th, 2026
Jazz Pharmaceuticals Q2 revenue beats estimates at $1.21B, ups guidance to $4.68B

Jazz Pharmaceuticals reported a strong second quarter with revenue of $1.21 billion, beating analyst estimates of $1.12 billion and representing 15.5% year-on-year growth. The company raised its full-year revenue guidance to $4.68 billion from $4.38 billion. CEO Renée Galá attributed the performance to strong demand for flagship products like Xywav and Epidiolex, alongside accelerating uptake of new oncology therapies. Operating margin improved to 20.5%, up from negative 65.6% in the prior year quarter. However, adjusted earnings per share of $5.71 missed analyst expectations of $6.18. During the earnings call, analysts focused on Epidiolex's growth drivers, Xywav's sustainability amid potential generic competition, and zanidatamab's upcoming approval prospects.

Yahoo Finance
Aug 11th, 2026
Jazz Pharma raises 2026 guidance on record Q2 revenue of $1.2B, up 16%

Jazz Pharmaceuticals reported record second quarter revenue of $1.2 billion, representing 16% year-over-year growth. The company raised its full-year revenue guidance based on strong first-half performance. Chief executive officer Renée Galá attributed the results to execution across the company's diversified portfolio and sustained demand for its commercial products. The company is preparing to launch zanidatamab, with a PDUFA date of 25 August for treatment of first-line HER2-positive metastatic gastroesophageal adenocarcinoma. The earnings call included updates from senior leadership, including chief commercial officer Samantha Pearce, global head of research and development Robert Iannone, and chief financial officer Philip Johnson. Jazz Pharmaceuticals highlighted progress on its long-term value creation priorities whilst maintaining focus on current commercial operations.

Yahoo Finance
Aug 10th, 2026
Jazz Pharmaceuticals to acquire Actio Biosciences for $820M upfront, adding KCNT1+ epilepsy therapy

Jazz Pharmaceuticals has agreed to acquire Actio Biosciences for $820 million upfront and up to $500 million in contingent payments. The deal adds ABS-1230, a clinical-stage precision therapy for KCNT1+ epilepsy, to Jazz's rare epilepsy portfolio. KCNT1+ epilepsy is a rare genetic condition affecting approximately 2,500 patients in the United States. Patients typically experience dozens to hundreds of seizures daily that resist standard medications. Around 80% of cases begin in infancy, with many children unable to reach basic developmental milestones. There are currently no FDA-approved therapies for KCNT1+ epilepsy. ABS-1230 recently showed meaningful seizure reductions in an early clinical trial. The ongoing Phase 1b/2a KYRON trial is designed as the registrational study supporting US new drug application submission.